B
275.28
-7.44 (-2.63%)
| Previous Close | 282.72 |
| Open | 282.43 |
| Volume | 220,667 |
| Avg. Volume (3M) | 271,328 |
| Market Cap | 31,617,419,264 |
| Price / Earnings (TTM) | 111.00 |
| Price / Earnings (Forward) | 50.00 |
| Price / Sales | 6.15 |
| Price / Book | 7.37 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -9.40% |
| Operating Margin (TTM) | 0.99% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | 48.60% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 212.02 M |
| Levered Free Cash Flow (TTM) | -120.68 M |
| Return on Assets (TTM) | -3.22% |
| Return on Equity (TTM) | -11.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BeOne Medicines Ltd. | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.40 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 17.31% |
| % Held by Institutions | 43.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capital International, Inc./Ca/ | 31 Dec 2025 | 307,660 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 425.00 (RBC Capital, 54.39%) | Buy |
| Median | 411.00 (49.30%) | |
| Low | 405.00 (Barclays, 47.12%) | Buy |
| Average | 413.00 (50.03%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 316.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 27 Feb 2026 | 405.00 (47.12%) | Buy | 316.99 |
| 04 Feb 2026 | 394.00 (43.13%) | Buy | 352.00 | |
| Guggenheim | 27 Feb 2026 | 410.00 (48.94%) | Buy | 316.99 |
| RBC Capital | 27 Feb 2026 | 425.00 (54.39%) | Buy | 316.99 |
| Truist Securities | 27 Feb 2026 | 412.00 (49.67%) | Buy | 316.99 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LEE CHAN HENRY | - | 298.91 | -341 | -101,928 |
| Aggregate Net Quantity | -341 | |||
| Aggregate Net Value ($) | -101,928 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 298.91 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LEE CHAN HENRY | Officer | 11 Mar 2026 | Automatic sell (-) | 341 | 298.91 | 101,928 |
| LEE CHAN HENRY | Officer | 11 Mar 2026 | Option execute | 341 | - | - |
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference |
| 06 Jan 2026 | Announcement | ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA |
| 23 Dec 2025 | Announcement | BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |